Why I'm Not Worried About Teladoc's Q2 Earnings Miss
As a Teladoc Health (NYSE: TDOC) shareholder, I cringed when I saw the stock's initial sell-off on July 28, the day the company released its second-quarter results last week -- it fell as much as 11.8% before recovering. Often, a stock's price after earnings provides a good sense of how good or bad the numvers were. But it can also be misleading in many cases, especially when investors overreact.
That's what I believe happened with Teladoc -- the earnings report wasn't nearly as bad as I expected it to be based on the reaction. Although the company's net loss of $0.86 per share was worse than the $0.56 loss analysts were expecting, it was actually a pretty good quarter for the company, and there were many positives to pull from it.
Image source: Getty Images.
Source Fool.com
